Evidence of Clinical Effectiveness and Data Requirements For an NDA

Eileen Navarro, MD, FACP
Disclaimer

Opinions expressed do not reflect official FDA policy
Outline

• Evidence of Clinical Effectiveness
  – Adequate and well controlled trials
  – Endpoints of direct clinical benefit
  – Evidentiary requirements in incentive programs

• Submission Requirements
  – Content
  – Format
Statutory Requirement
(Sec 505  FFDCA)

(a) Need an approved application to market

(b)(1) Full reports of investigations = safe and effective
      Details components, composition, methods & controls

(c) FDA must give positive approval (change - 1962 KHAA)
The Food, Drug and Cosmetic Act of 1938

Required premarket notification.

Required a demonstration of safety for approval.

Basis of refusal:

(a) did not include ALL tests reasonably applicable to show whether drug is safe when used under proposed labeling

(b) testing shows drug unsafe or do not show that it is safe

(c) information submitted or any other information available are insufficient to determine whether safe

(d) labeling is false or misleading in any particular
Keyfauver Harris Amendments 1962

1. FDA had to actively grant approval before a drug could be marketed

2. Requirement to study drugs under an IND; informed consent

3. The effectiveness requirement:
   Substantial evidence that the drug will have the effect it purports or is represented to have under proposed labeled conditions of use.
Drug Regulation History

- **1970s** drug lag
- **1980s** access to investigational drugs
- **PDUFA 1992** review timelines S/P 10/6 m
- **FDAMA 1997** fast track (drugs for serious disease that fill an unmet need)
- **BT PRA 2002** electronic applications and submissions
- **FDAAA 2007** authorities for safety assessment
- **FDASIA 2012** broad ranging changes:
  - UFA expansion, innovative incentives,
  - patient perspectives on benefit risk,
  - supply chain, shortages, standards mandates, subgroup outcomes
Benefit - Risk
Adequate directions for use and not false or misleading

- dose-response
- outcomes by relevant subgroup (age, gender, race)

21 CFR 314.50 mandates

FDASIA Section 907 trial participation, safety & efficacy outcome by age, gender, race
Regulations that affect an NDA Submission

21CFR 314.50: Content & Format of an Application

21CFR 314.126: Adequate & Well-Controlled Studies

21CFR 314.500: Accelerated approval (use of surrogate endpoints and approval with restrictions)
Clinical Effectiveness

“Substantial evidence consists of adequate and well-controlled investigations including clinical investigations...on the basis of which it could be concluded that the drug will have the effect it is represented to have under the conditions of use proposed in labeling.”

FDAMA 1997 – allow 1 study in certain circumstances
Effectiveness – “clinically meaningful” added in court
“Well controlled studies of adequate design must show effectiveness, ordinarily a statistically significant effect on a clinically meaningful endpoint, usually replicated, as a basis for approval. “

Robert Temple
Adequate & Well-Controlled Studies

Is it the drug or spontaneous change or influence of bias?

CONTROL & TEST groups identical save for exposure to test agent

How are test & control selected, treated, observed or analyzed pre-study, during, post study?

DESIGN CONDUCT ANALYSIS
Characteristics of an AWC Trial
21 CFR312 (b)Cliff notes version

• PRE - define a win, and **by how much**
• Design - powered to show **difference or no difference**
• Who is included/excluded in the trial? In the analysis?
• How to protect vs bias? Randomization, blinding
• What is measured? How reliably is it measured?
• PROTOCOL and STUDY REPORT – enable validation of study findings
ENDPOINTS

Distinct and measurable characteristics of treatment outcome

21 CFR 314.126(b)(6)
“The methods of assessment ... are well-defined and reliable.”

Well defined
“effect on how a patient survives, feels or functions. others .... are surrogate measures of benefit”

Endpoints

• Composite Endpoints – multiple ways to win?
  – When outcomes are discordant
  – Which component drives a win
  – Which component is sensitive to drug effect

• Measuring Endpoints
  - Patient Reported Outcomes, Biomarkers

• Methods of Collection
  – Standards enhance replication, balance with flexibility
2 Studies, each convincing on its own, except..

“excellent multicenter study with statistically strong finding,” OR

“where .. an important clinical benefit, (e.g. superiority in mortality), made a confirmatory study difficult to conduct on ethical grounds”.

SO, A VERY HIGH BAR to conduct a SINGLE AWC study.
Regulatory Flexibility: Clinical Effectiveness Guidance

1. AWCS + independent substantiation confirming efficacy
   - different doses, regimens, dosage forms, endpoints
   - another disease phase or population
   - similar purpose, pharmacologic/pathophysiologic correlation
1 AWCS (no confirmatory data needed)
  – multicenter study, consist across sites & patient subsets
  – factorial studies
  – multiple endpoints, different events
  – statistically persuasive finding
FDA fast-tracks drug to treat Duchenne muscular dystrophy

August 31, 2015 12:00 AM
New drug works differently from statins to lower "bad" LDL cholesterol. The FDA has approved Repatha for people with hereditary forms of high cholesterol or a high risk of cardiovascular disease whose LDL cholesterol can’t be controlled with current medications.

"Repatha provides another treatment option in this new class of drugs for patients with familial hypercholesterolemia or with known cardiovascular disease who have not been able to lower their LDL cholesterol enough with statins," says John Jenkins, M.D., director of the FDA’s Office of New Drugs, Center for Drug Evaluation and Research. "Cardiovascular disease is a serious threat to the health of Americans, and the FDA is committed to facilitating the development and approval of effective and safe drugs to address this important public health problem."
2013 Guidance: Expedited Programs for Serious Conditions

What is a Serious Condition? 57 FR 58942, 1992

For which products are these incentives available?

https://www.federalregister.gov/articles/2013/06/26/2013-15250/draft-guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics

*superceded Guidance for Industry: Fast Track Drug Development Program –Designation, Development and Review
Guidance: Expedited Programs for Serious Conditions

What is Unmet need?

What is Existing or Available therapy?

Is Unapproved or unregulated Rx “available therapy”?

https://www.federalregister.gov/articles/2013/06/26/2013-15250/draft-guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics

*superceded Guidance for Industry: Fast Track Drug Development Program –Designation, Development and Review
Guidance: Expedited Programs for Serious Conditions

Even when not shown to have an efficacy or safety advantage –

“a novel mechanism of action with a well-understood relationship to the disease pathophysiology.

A reasonable basis for concluding that a significant number of patients may respond differently”

For example, mechanistic diversity, .....could be advantageous in disease settings in which drugs become less effective or ineffective over time.”

“preferable to have more than one treatment approved under accelerated approval regulations because benefit may not be verified in confirmatory trials for already approved products.”

https://www.federalregister.gov/articles/2013/06/26/2013-15250/draft-guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics

*superceded Guidance for Industry: Fast Track Drug Development Program –Designation, Development and Review
Harmonized Critical Guidance

ICH E3  Structure and Content of Clinical Study Reports
ICH E4  Dose-Response Information
ICH E5  Ethnic Factors
ICH E6  Good Clinical Practise
ICH E9  Statistical Principles
ICH E10 Choice of Control Group
ICH M4  electronic Common Technical Document
ICH M4  Efficacy / Safety

http://www.fda.gov/RegulatoryInformation/Guidances/default.htm
Content and Format of an Application
ICH Common Technical Document

Modules
M1: Administrative
M2: Summaries
M3: Product Quality
M4: Non-clinical
M5: Clinical
Content and Format of an Application (21 CFR 314.50), ICH Common Technical Document

Module 5
Clinical Study Reports
5
5.1 T of C

(1) human pharmacokinetics
(2) microbiology
(3) clinical data
(4) statistical section
(7) pediatric use
(8) CRF and CRT
1. Description & analysis of every study. Reports of everything ..pertinent to safety and effectiveness from any source.

2. Summary of ..effectiveness, support (for) dosage and administration, modifications for subgroups (e.g. age, renal function).

3. Safety summary, 4 month update of all available information (animal data, adverse effects, drug-drug interactions).
Clinical Section (continued)

4. Case report forms for deaths and discontinuations
   Others on request. Pre 1985, all CRFs required.

5. Case report tabulations. (replaced “all CRFs”)
   All data from well-controlled studies
   All data from earliest clinical pharm studies
   Safety data from other studies
Module M5

M5: Clinical Study Reports

- Integrated Summary of Safety (ISS)
- Integrated Summary of Efficacy (ISE)

- Datasets (5.3.5.1.25)
  - Electronic datasets (5.3.5.1.25.3)
  - Define files (5.3.5.1.25.3.3)
Clinical Filing Checklist for Day 45 meeting:

• Are datasets available for all pivotal trials?
• Are they reliable, transparent and traceable to the CRF?
• Do the datasets reflect the Sponsor’s report of dosage, treatment arms, adequate exposure of doses and duration?
• Are the datasets in a format to allow review of patient data? Are endpoints, adverse events evaluable?
• Is the raw data available to derive the composite endpoints? Do the data allow replication of findings?
• Request data needed that is not submitted
• Pick the trial sites for audit
Clinical Filing Checklist- selected sections:

<table>
<thead>
<tr>
<th>Content Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FORMAT/ORGANIZATION/LEGIBILITY</strong></td>
</tr>
<tr>
<td>1. Identify the general format that has been used for this application, e.g. electronic CTD.</td>
</tr>
<tr>
<td>2. On its face, is the clinical section organized in a manner to allow substantive review to begin?</td>
</tr>
<tr>
<td>3. Is the clinical section indexed (using a table of contents) and paginated in a manner to allow substantive review to begin?</td>
</tr>
<tr>
<td>4. For an electronic submission, is it possible to navigate the application in order to allow a substantive review to begin (e.g., are the bookmarks adequate)?</td>
</tr>
<tr>
<td>5. Are all documents submitted in English or are English translations provided when necessary?</td>
</tr>
<tr>
<td>6. Is the clinical section legible so that substantive review can begin?</td>
</tr>
</tbody>
</table>

**LABELING**

| 7. Has the applicant submitted the design of the development package and draft labeling in electronic format consistent with current regulation, divisional, and Center policies? |
PDUFA V Included the Requirement to Submit Standardized Electronic Data

- 2002 PDUFA III
- 2012 PDUFA V
- 2014 progress in implementation
  - Final 745A(a) Guidance
  - Guidance for Industry - Providing Regulatory Submissions in Electronic Format - Standardized Study Data ("eStudy Data Guidance")
  - Data Standards Catalog
  - Technical Conformance Guide
  - Study Data Reviewer’s Guide (SDRG)
**When** will Study Data Standards will be Required?

24 months post estudy guidance issuance, December 2016

**What** Study Data Standards will be Required?

http://www.fda.gov/forindustry/datastandards/studydatastandards/default.htm

**How** will Study Data Standards be Required?

Study Data Standardization Plan

IND:
- List of the planned studies,
- Study phase,
- Study design
- Planned data standards, formats, terminologies OR justification of studies that may not conform

NDA:
cover letter should describe if Standardization Plan was executed
Resources

Data Standards Catalog
Study Data Technical Conformance Guide


• [http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm)
Conclusions

• Adequate and well controlled studies are the basis for a successful NDA; planning starts in IND
• Adequate evidence: rooted in science, codified in regulation, validated in review, described in label
• GCP is reflected in quality submissions; standards facilitate labeling of efficacy and safety
• The electronic submissions and data standards are required by law
• Greater harmonization of regulatory requirements
• Key requirements for Phase III and Market authorization - Understand differences and similarities to EU drug approval process - Available advise and support by FDA for small enterprises
• Will Drug Products be discussed along with Drug Substances where applicable? Aids, cancer, diabetes, viral autoimmune
• DMF document via ectd
Thanks!
Slides from colleagues and OND/CDER training

Questions?

Please complete the session survey:

 surveymonkey.com/r/DRG-D2S7